{"id":37954,"date":"2025-07-25T14:50:44","date_gmt":"2025-07-25T06:50:44","guid":{"rendered":"https:\/\/flcube.com\/?p=37954"},"modified":"2025-07-25T14:50:45","modified_gmt":"2025-07-25T06:50:45","slug":"sinocelltechs-sct640c-injection-receives-nmpa-approval-for-ra-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37954","title":{"rendered":"SinoCellTech&#8217;s SCT640C Injection Receives NMPA Approval for RA Clinical Trials"},"content":{"rendered":"\n<p>China-based SinoCellTech Group Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688520:SHA\">SHA: 688520<\/a>) announced today that its self-developed product, SCT640C injection, has received approval from China&#8217;s National Medical Products Administration (NMPA) to begin clinical trials for the treatment of adult rheumatoid arthritis (RA). This marks a significant step forward in the development of novel therapies for this debilitating autoimmune disease.<\/p>\n\n\n\n<p><strong>About Rheumatoid Arthritis<\/strong><br>RA is a systemic autoimmune disease primarily characterized by chronic erosive arthritis. It can lead to severe complications such as lung diseases, cardiovascular and cerebrovascular diseases, osteoporosis, and malignancies. Current treatments often focus on managing symptoms and slowing disease progression, but there remains a significant unmet need for more effective therapies.<\/p>\n\n\n\n<p><strong>SCT640C: A Promising New Therapy<\/strong><br>SCT640C is a monoclonal antibody injection developed by SinoCellTech. It is designed to provide a differentiated competitive advantage in the treatment of autoimmune diseases. The approval to proceed with clinical trials represents a crucial milestone in bringing this potential new treatment option to patients suffering from RA.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/688520_20250725_6KMU.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688520_20250725_6KMU.\"><\/object><a id=\"wp-block-file--media-2ca83f80-f4b2-41b0-a8f2-49591b69ca77\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/688520_20250725_6KMU.pdf\">688520_20250725_6KMU<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/688520_20250725_6KMU.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2ca83f80-f4b2-41b0-a8f2-49591b69ca77\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37956,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,62,1090,252],"class_list":["post-37954","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-approval-initiation","tag-sha-688520","tag-sinocelltech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SinoCellTech&#039;s SCT640C Injection Receives NMPA Approval for RA Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has received approval from China&#039;s National Medical Products Administration (NMPA) to begin clinical trials for the treatment of adult rheumatoid arthritis (RA). This marks a significant step forward in the development of novel therapies for this debilitating autoimmune disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37954\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SinoCellTech&#039;s SCT640C Injection Receives NMPA Approval for RA Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has received approval from China&#039;s National Medical Products Administration (NMPA) to begin clinical trials for the treatment of adult rheumatoid arthritis (RA). This marks a significant step forward in the development of novel therapies for this debilitating autoimmune disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37954\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-25T06:50:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-25T06:50:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2510.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"646\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37954#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37954\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SinoCellTech&#8217;s SCT640C Injection Receives NMPA Approval for RA Clinical Trials\",\"datePublished\":\"2025-07-25T06:50:44+00:00\",\"dateModified\":\"2025-07-25T06:50:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37954\"},\"wordCount\":180,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37954#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2510.webp\",\"keywords\":[\"Auto-immune\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688520\",\"Sinocelltech\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37954#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37954\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37954\",\"name\":\"SinoCellTech's SCT640C Injection Receives NMPA Approval for RA Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37954#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37954#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2510.webp\",\"datePublished\":\"2025-07-25T06:50:44+00:00\",\"dateModified\":\"2025-07-25T06:50:45+00:00\",\"description\":\"China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has received approval from China's National Medical Products Administration (NMPA) to begin clinical trials for the treatment of adult rheumatoid arthritis (RA). This marks a significant step forward in the development of novel therapies for this debilitating autoimmune disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37954#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37954\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37954#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2510.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2510.webp\",\"width\":1080,\"height\":646,\"caption\":\"SinoCellTech's SCT640C Injection Receives NMPA Approval for RA Clinical Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37954#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SinoCellTech&#8217;s SCT640C Injection Receives NMPA Approval for RA Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SinoCellTech's SCT640C Injection Receives NMPA Approval for RA Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has received approval from China's National Medical Products Administration (NMPA) to begin clinical trials for the treatment of adult rheumatoid arthritis (RA). This marks a significant step forward in the development of novel therapies for this debilitating autoimmune disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37954","og_locale":"en_US","og_type":"article","og_title":"SinoCellTech's SCT640C Injection Receives NMPA Approval for RA Clinical Trials","og_description":"China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has received approval from China's National Medical Products Administration (NMPA) to begin clinical trials for the treatment of adult rheumatoid arthritis (RA). This marks a significant step forward in the development of novel therapies for this debilitating autoimmune disease.","og_url":"https:\/\/flcube.com\/?p=37954","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-25T06:50:44+00:00","article_modified_time":"2025-07-25T06:50:45+00:00","og_image":[{"width":1080,"height":646,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2510.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37954#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37954"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SinoCellTech&#8217;s SCT640C Injection Receives NMPA Approval for RA Clinical Trials","datePublished":"2025-07-25T06:50:44+00:00","dateModified":"2025-07-25T06:50:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37954"},"wordCount":180,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37954#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2510.webp","keywords":["Auto-immune","Clinical trial approval \/ initiation","SHA: 688520","Sinocelltech"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37954#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37954","url":"https:\/\/flcube.com\/?p=37954","name":"SinoCellTech's SCT640C Injection Receives NMPA Approval for RA Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37954#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37954#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2510.webp","datePublished":"2025-07-25T06:50:44+00:00","dateModified":"2025-07-25T06:50:45+00:00","description":"China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has received approval from China's National Medical Products Administration (NMPA) to begin clinical trials for the treatment of adult rheumatoid arthritis (RA). This marks a significant step forward in the development of novel therapies for this debilitating autoimmune disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37954#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37954"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37954#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2510.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2510.webp","width":1080,"height":646,"caption":"SinoCellTech's SCT640C Injection Receives NMPA Approval for RA Clinical Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37954#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SinoCellTech&#8217;s SCT640C Injection Receives NMPA Approval for RA Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2510.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37954"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37954\/revisions"}],"predecessor-version":[{"id":37957,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37954\/revisions\/37957"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37956"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}